Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone for Opioid Associated Out of Hospital Cardiac Arrest
NCT06251609Phase 2
Key facts
- Status
- Not yet recruiting
- Start
- Mar 2027
- Primary completion
- Feb 2029
- Countries
- 1
- Sponsor
- University of California, San Francisco
- Modality
- Orthosteric Ligands
- Drugs
- naloxone
- Conditions
- cardiac arrest (SCA)opioid overdose
01
Overview
Phase 2, randomised, double-blind trial of naloxone in cardiac arrest (SCA) and opioid overdose (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Survival to hospital discharge at 5 days. Planned start Mar 2027; status: not yet recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Naloxone
Naloxone 2mg (2ml of 1mg/ml solution) administered by EMS personnel via IV or IO route.
Saline
Saline 2ml supplied in pre-filled syringes administered by EMS personnel via IV or IO route.
03
Who it enrols
Adults under 60 years old with out-of-hospital cardiac arrest presumed to be opioid-related, who have received initial ACLS including epinephrine. Excludes patients with cardiac arrest caused by trauma, choking, or drowning, pregnant patients, and those who achieve ROSC prior to study drug administration.
04
Endpoints
Primary
Survival to hospital discharge
Secondary
Sustained Return of Spontaneous Circulation
Beyond the preview
Go deeper on NCT06251609.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06251609.